KRAS and colorectal cancer: In a survey conducted as input into the analysis of an economic evaluation, Barone et al. [59], an Italian research team, found that 75% of a sample of oncologists, pathologists, molecular biologists and surgeons believed a delay in receiving KRAS mutation testing result for colorectal cancer patients would affect their treatment choice and that 25% experienced such delays in actual practice.